Diabetes Care, Management and the Importance of Glucose Monitoring Systems [Interview][Transcript]
Key Takeaways
- Key Insight: Mahmood Kazemi Presenter: Tabetha Moreto Guest Bio: Dr.
- Clinical Perspective: Mahmood Kazemi MD, FACE (Fellow of the American Association of Clinical Endocrinologists) is the Senior Director of Global Medical & Scientific Affairs of Abbott’s diabetes care unit.
- Why It Matters: This discussion provides healthcare professionals with actionable insights relevant to clinical practice and patient care.
- Key Point: Listen to the full episode for detailed discussion and professional insights on this important healthcare topic.
- Key Point: Listen to the full episode for detailed discussion and professional insights on this important healthcare topic.
Guest: Dr. Mahmood Kazemi
Presenter: Tabetha Moreto
Guest Bio: Dr. Mahmood Kazemi MD, FACE (Fellow of the American Association of Clinical Endocrinologists) is the Senior Director of Global Medical & Scientific Affairs of Abbott’s diabetes care unit. Prior to this role, Dr. Kazemi was the Medical Director at Sanofi. Dr. Kazemi was also previously in the private Endocrinology practice, while also being the Assistant Clinical Professor of Medicine at the University of California’s San Francisco Division of Diabetes.
Dr. Kazemi earned his Bachelors and Masters degrees from Stanford University, and his medical degree from University of California San Francisco.
Segment overview: In today’s Health Supplier Segment, we are joined by Senior Director, Global Medical and Scientific Affairs Abbott, Diabetes Care Dr. Mahmood Kazemi here to discuss diabetes care and management as well as the FreeStyle Libre Flash Glucose Monitoring System. This is a glucose monitoring device indicated for detecting trends and tracking patterns in persons aged 18 and older with insulin dependent diabetes mellitus. Currently, the Australian Government’s Department of Health is conducting an evaluation of the FreeStyle Libre Flash Glucose Monitoring (FGM) product to consider its suitability for subsidisation under the National Diabetes Services Scheme. The Assessment panel will take into account FGM’s clinical effectiveness, safety and cost effectiveness.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
